低级别浆液性卵巢癌中的mRNA表达:在多样化人群中nanoString检测的结果
本研究利用机构肿瘤登记处识别低级别浆液性卵巢癌患者,分析体细胞突变与基因转录模式。39例患者中黑人占20%、西班牙裔占43%、非西班牙裔白人占36%。KRAS突变最常见(11例,61%),在吸烟者中较少见(14.3% vs 90.9%,p=0.002)。HRAS在老年患者和复发肿瘤中表达下降超过两倍。不同种族和族裔队列间体细胞检测结果、RNA表达分析或无线生存期未见显著差异。
要点
- KRAS突变在低级别浆液性卵巢癌中常见(11例,61%),但在吸烟者中较少见(14.3% vs 90.9%,p=0.002)。
- HRAS在老年患者肿瘤中表达下降超过两倍(p=0.04),在复发肿瘤中表达下降超过两倍(p=0.007)。
- 不同种族和族裔队列间体细胞检测结果、RNA表达分析或无线生存期未见显著差异。
核心结论
- ERCC1、TUBB3和KRAS的体细胞缺陷在少数族裔低级别浆液性卵巢癌患者中常见。
- HRAS在老年患者和复发肿瘤中表达下降。
- 不同种族和族裔队列间体细胞检测结果、RNA表达分析或无线生存期未见显著差异。
研究设计与样本
- 利用机构肿瘤登记处识别低级别浆液性卵巢癌患者并复习病历。
- 从可用肿瘤组织提取RNA,用PanCancer pathway nanoString mRNA表达数据分析商业肿瘤分析结果。
- 统计分析使用nanoString n-Solver软件、卡方检验、Fisher精确检验和Cox比例风险模型,显著性设定为p<0.05。
- 共识别39例患者,其中20%黑人、43%西班牙裔、36%非西班牙裔白人。
- 18例有商业体细胞DNA检测结果,23例有可用肿瘤组织进行RNA提取和nanoString分析。
主要发现
- 最常见的体细胞改变是KRAS(11例,61%),其次是ERCC1和TUBB3(各9例,50%)。
- KRAS突变在吸烟者中较少见(14.3% vs 90.9%,p=0.002)。
- RNA表达分析显示,老年患者肿瘤中HRAS表达下降超过两倍(p=0.04),复发肿瘤中HRAS表达下降超过两倍(p=0.007)。
- 不同种族和族裔队列间体细胞检测结果、RNA表达分析或无线生存期未见显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Mutations in the MAP kinase pathway (KRAS, NRAS, BRAF) are common in low grade serous ovarian carcinoma (LGSOC). The effect of these and other mutations on RNA transcription in this disease is poorly understood. Our objective was to describe patterns of somatic mutations and gene transcription in a racially diverse population with LGSOC. METHODS: Utilizing an institutional tumor registry, patients with LGSOC were identified and charts were reviewed. RNA was extracted from available tumor tissue. Commercial tumor profiling results were analyzed with PanCancer pathway nanoString mRNA expression data. Along with nanoString n-Solver software, Chi-squared, Fishers Exact, and Cox proportional hazards models were used for statistical analysis, with significance set at p < 0.05. RESULTS: 39 patients were identified-20% Black, 43% Hispanic, and 36% non-Hispanic White. 18 patients had commercial somatic DNA test results, and 23 had available tumor tissue for RNA extraction and nanoString analysis. The most common somatic alterations identified was KRAS (11 patients, 61%), followed by ERCC1 and TUBB3 (9 each, 50%). KRAS mutations were less common in smokers (14.3% vs 90.9%, p = 0.002). RNA expression analysis demonstrated a greater than two-fold decrease in expression of HRAS in tumors from older patients (p = 0.04), and a greater than two-fold decrease in the expression of HRAS in recurrent tumors (p = 0.007). No significant differences were seen in somatic testing results, RNA expression analysis, or progression free survival between different racial and ethnic cohorts. CONCLUSIONS: Somatic deficiencies in ERCC1, TUBB3, and KRAS are common in LGSOC in a population of minority patients. HRAS demonstrates decreased expression in tumors from older patients and recurrent tumors.
引用
- Jordan SE, Saad H, Covarrubias AS, et al. mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population. Gynecol Oncol. 2020. PMID: 32951896. doi:10.1016/j.ygyno.2020.08.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。